Arcoma AB

Stockholm Stock Exchange ARCOMA.ST

Arcoma AB Return on Capital Employed (ROCE) for the year ending December 31, 2023: 8.91%

Arcoma AB Return on Capital Employed (ROCE) is 8.91% for the year ending December 31, 2023, a 47.24% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Arcoma AB Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 6.05%, a 134.34% change year over year.
Arcoma AB Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -17.63%, a -362.50% change year over year.
Arcoma AB Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 6.72%, a -67.03% change year over year.
Arcoma AB Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 20.37%, a 2,201.85% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: ARCOMA.ST

Arcoma AB

CEO	Mr. Mattias Leire
IPO Date	Nov. 14, 2014
Location	Sweden
Headquarters	AnnavAegen 1
Employees	32
Sector	Technology
Industries 3D Printing Automotive Parts Biotechnology Composite Materials Defense & Military Medical Instruments Pharmaceuticals Robotics

Description

Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in Växjö, Sweden.

Key trends

Past 5 years